Indicia Production announces acquisition of Bio-Steril
Indicia Production, a Contract Manufacturing Organisation specialising in the manufacture of ready-to-use microbiological media and sterile pharmaceutical ingredients, has announced the acquisition of Bio-Steril, a French company that specialises in the formulation and Fill & Finish of medical devices for cosmetic and medical uses. The financial terms of the transaction have not been disclosed.
This allows Indicia to extend its manufacturing capabilities and open new market areas, such as dermo-aesthetics, ophthalmology and rheumatology. It also means that Indicia can now provide a highly specialised manufacturing area dedicated to the filling of dermal filler in syringes.
Created in June 2004, Bio-Steril is a CMO specialised in the production of sterile medical devices and cosmetics liquids and gels. Based on customer’s either bulk or in-house formulated products, Bio-Steril produces sterile pre-filled syringes, vials and glassware. Manufacturing is achieved in clean rooms of ISO 7 and ISO 8 standards, while filling is done under ISO 5 conditions. A wide variety of final packaging is available. The company is certfied ISO13485.
“I am very happy with this new acquisition, which perfectly complements our current offer,” said Stephane Legastelois, chairman and CEO of Indicia Production. “Bio-Steril’s know-how will be very valuable to our customers.”
“Indicia Production is a well-known company and we are very pleased to join its ranks,” said René Trehorel, chairman of Bio-Steril. “We offer very specific know-how in sterilisation and production of sterile medical devices which will enhance Indicia’s global offer.”
Indicia Production currently offers three product families:
- Ready-to-use microbiological culture media for a client base; comprising distributors and industry providers of control tests for the pharmaceutical, food processing and cosmetics industries
- Sterile excipient, raw materials and reagents for the pharmaceutical and cosmetics industries
- Medical devices
As a recognised player in the field of OEM manufacturing of sterile ingredients, Indicia conforms to Good Manufacturing Practices and ISO 13485 environments, both required for the manufacturing of pharmaceutical excipients and medical devices.
The consolidated company will operate with 85 employees. Its combined turnover for 2019 is estimated to reach €12.5-million.
Back to Homepage
Back to Healthcare